Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma

  • Maria João Marques Ribeiro Centro Hospitalar S. João, Clinical Oncology Department
  • Teresa Alonso Hospital Universitário Ramón y Cajal, Clinical Oncology Department
  • Pablo Gajate Hospital Universitário Ramón y Cajal, Clinical Oncology Department
  • Javier Molina Hospital Universitário Ramón y Cajal, Clinical Oncology Department
  • Arantzazu Barquin Hospital Universitário Ramón y Cajal, Clinical Oncology Department
  • Cristian Perna Hospital Universitário Ramón y Cajal, Pathology Department
  • Enrique Grande Hospital Universitário Ramón y Cajal, Clinical Oncology Department
Keywords: Carcinoma, Neuroendocrine, Stomach Neoplasms, Neoplasm Metastases, Medical Oncology.

Abstract

Chemotherapy is considered “state of the art” for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor activity.

Downloads

Download data is not yet available.
Published
2018-03-13
How to Cite
Ribeiro, M. J., Alonso, T., Gajate, P., Molina, J., Barquin, A., Perna, C., & Grande, E. (2018). Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autopsy and Case Reports, 8(1), e2018005. https://doi.org/10.4322/acr.2018.005
Section
Article / Clinical Case Report